Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy PolicyMICROB-PREDICT Results Videos: Sharing our innovation with scientists and liver patients
As the project approaches the finish line (September 2026), MICROB-PREDICT has launched a comprehensive 17-part results video series to showcase its scientific achievements and maximise the project's long-term impact. The collection includes eight Expert Presentations highlighting key discoveries on biomarkers, microbiome research, multi-omics, gut barrier dysfunction, metabolomics and novel therapeutic targets for cirrhosis and ACLF, alongside nine Easy Results Videos that translate these advances for patients and the general public - featuring ELPA president Marko Korenjak as interviewer. Together, these video series help bridge the gap between research, clinical practice, and patient understanding, ensuring that MICROB-PREDICT's discoveries continue to inform both future liver disease research and improved care for patients.
More newsMICROB-PREDICT at EASL 2026: Driving advances in precision hepatology
In the final project year, MICROB-PREDICT consortium members showcased their work with an exceptionally strong presence at EASL Congress in Barcelona from 27-30 May 2026, contributing more than 50 activities (oral presentations, posters, educational sessions and symposia on biomarkers, microbiome-host interactions, cirrhosis, portal hypertension, liver transplantation, precision medicine, as well as promotional visuals and info materials about MICROB-PREDICT itself). A key highlight was the MICROB-PREDICT Consensus Conference on 27 May, followed by a dedicated Networking Session on 30 May - presenting the consensus outcomes on microbiome-based mechanisms and biomarkers for improved patient stratification and care in cirrhosis and ACLF. Congratulations to the entire team for the fantastic representation!
More newsMICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news